Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...

MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...

Figure 1:Human LAG-3 homodimer (with domains D1, D2, D3 and D4) binding to two separate HLA-II (MHC-II) molecules on the surface of an antigen-presenting cell (APC), imposing a distinct 38° offset ...

It is well known that the biggest genetic risk factor for the autoimmune disease systemic lupus erythematosus (SLE) is major histocompatibility complex class II (MHC-II). What remains unclear is the ...